Targeting Bone Metastases with a Bispecific Anticancer and Antiangiogenic Polymer-Alendronate-Taxane Conjugate

被引：161

作者：

Miller, Keren ^{[1
]}

Erez, Rotem ^{[2
]}

Segal, Ehud ^{[1
]}

Shabat, Doron ^{[2
]}

Satchi-Fainaro, Ronit ^{[1
]}

机构：

[1] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel

[2] Raymond & Beverly Sackler Fac Exact Sci, Sch Chem, Dept Organ Chem, Tel Aviv, Israel

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2009年 / 48卷 / 16期

基金：

以色列科学基金会;

关键词：

angiogenesis; antitumor agents; bone metastases; nanoconjugates; polymers; DRUG-DELIVERY SYSTEMS; CATHEPSIN-B; PROSTATE-CANCER; BREAST-CANCER; HPMA COPOLYMER; BRAIN-TUMORS; PACLITAXEL; THERAPEUTICS; ANGIOGENESIS; CHEMOTHERAPY;

D O I：

10.1002/anie.200805133

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

A polymer therapeutic designed for combination anticancer and antiangiogenic therapy inhibited the proliferation of prostate carcinoma cells and the proliferation, migration, and tube-formation of endothelial cells. The nanoconjugate was formed from an N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer, the bisphosphonate alendronate (for bone targeting), and the chemotherapy agent paclitaxel (PTX), which is cleaved by cathepsin B (see scheme). © 2009 Wiley-VCH Verlag GmbH & Co. KGaA.

引用

页码：2949 / 2954

页数：6

共 48 条

[1]

[Anonymous], 2005, ANGEW CHEM

[2] Microtubule-targeted anticancer agents and apoptosis [J].

Bhalla, KN .

ONCOGENE, 2003, 22 (56) :9075-9086

[3]

Browder T, 2000, CANCER RES, V60, P1878

[4] Emerging anti-cancer molecular mechanisms of aminobisphosphonates [J].

Caraglia, M ;

Santini, D ;

Marra, M ;

Vincenzi, B ;

Tonini, G ;

Budillon, A .

[5] Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer [J].

Cetnar, Jeremy P. ;

Malkowicz, Bruce ;

Palmer, Steven C. ;

Wein, Alan J. ;

Vaughn, David J. .

UROLOGY, 2008, 71 (05) :942-946

[6] Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma [J].

Chesler, Louis ;

Goldenberg, David D. ;

Seales, Isha T. ;

Satchi-Fainaro, Ronit ;

Grimmer, Matt ;

Collins, Rodney ;

Struett, Chris ;

Nguyen, Kim N. ;

Kim, Grace ;

Tihan, Tarik ;

Bao, Yun ;

Brekken, Rolf A. ;

Bergers, Gabriele ;

Folkman, Judah ;

Weiss, William A. .

CANCER RESEARCH, 2007, 67 (19) :9435-9442

[7] Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer [J].

Decock, J. ;

Obermajer, N. ;

Vozelj, S. ;

Hendrickx, W. ;

Paridaens, R. ;

Kos, J. .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2008, 23 (03) :161-168

[8] Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel [J].

Desai, N ;

Trieu, V ;

Yao, ZW ;

Louie, L ;

Ci, S ;

Yang, A ;

Tao, CL ;

De, T ;

Beals, B ;

Dykes, D ;

Noker, P ;

Yao, R ;

Labao, E ;

Hawkins, M ;

Soon-Shiong, P .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1317-1324

[9] Cathepsin B-sensitive dipeptide prodrugs.: 2.: Models of anticancer drugs paclitaxel (Ttaxol®), mitomycin C and doxorubicin [J].

Dubowchik, GM ;

Mosure, K ;

Knipe, JO ;

Firestone, RA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) :3347-3352

[10] Designing polymer conjugates as lysosomotropic nanomedicines [J].

Duncan, R. .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :56-60

← 1 2 3 4 5 →